AU2020343329C1 - Methods of treatment - Google Patents

Methods of treatment

Info

Publication number
AU2020343329C1
AU2020343329C1 AU2020343329A AU2020343329A AU2020343329C1 AU 2020343329 C1 AU2020343329 C1 AU 2020343329C1 AU 2020343329 A AU2020343329 A AU 2020343329A AU 2020343329 A AU2020343329 A AU 2020343329A AU 2020343329 C1 AU2020343329 C1 AU 2020343329C1
Authority
AU
Australia
Prior art keywords
formula
substituted
alkyl
independently
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020343329A
Other languages
English (en)
Other versions
AU2020343329B2 (en
AU2020343329A1 (en
Inventor
Robert Davis
Peng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2020343329A1 publication Critical patent/AU2020343329A1/en
Publication of AU2020343329B2 publication Critical patent/AU2020343329B2/en
Application granted granted Critical
Publication of AU2020343329C1 publication Critical patent/AU2020343329C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020343329A 2019-09-03 2020-09-03 Methods of treatment Active AU2020343329C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962895476P 2019-09-03 2019-09-03
US62/895,476 2019-09-03
PCT/US2020/049248 WO2021046250A1 (en) 2019-09-03 2020-09-03 Methods of treatment

Publications (3)

Publication Number Publication Date
AU2020343329A1 AU2020343329A1 (en) 2022-03-24
AU2020343329B2 AU2020343329B2 (en) 2025-07-24
AU2020343329C1 true AU2020343329C1 (en) 2026-02-12

Family

ID=74853030

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020343329A Active AU2020343329C1 (en) 2019-09-03 2020-09-03 Methods of treatment

Country Status (11)

Country Link
US (1) US12599603B2 (cg-RX-API-DMAC10.html)
EP (1) EP4025218A4 (cg-RX-API-DMAC10.html)
JP (1) JP7631319B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220054853A (cg-RX-API-DMAC10.html)
CN (1) CN114340636A (cg-RX-API-DMAC10.html)
AU (1) AU2020343329C1 (cg-RX-API-DMAC10.html)
BR (1) BR112022003670A2 (cg-RX-API-DMAC10.html)
CA (1) CA3147071A1 (cg-RX-API-DMAC10.html)
IL (1) IL290983A (cg-RX-API-DMAC10.html)
MX (1) MX2022002607A (cg-RX-API-DMAC10.html)
WO (1) WO2021046250A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment
MX2024010993A (es) * 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322903A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
JP6224597B2 (ja) 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
DK3157926T3 (da) * 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US10131671B2 (en) * 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) * 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
US10849862B2 (en) * 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US10912748B2 (en) * 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
MA46716A (fr) 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
CA3047579A1 (en) 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
EP3612839A1 (en) 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy
AU2018325445A1 (en) 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
EP3856191A4 (en) 2018-09-25 2022-06-22 Intra-Cellular Therapies, Inc. NOVEL USES
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment
MX2024010993A (es) 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHNSON, J.J. MUKHTAR, H.: "Curcumin for chemoprevention of colon cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 255, no. 2, 8 October 2007 (2007-10-08), US, pages 170 - 181, XP022208114, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2007.03.005 *
PENG TING ET AL: "Inhibitors of phosphodiesterase as cancer therapeutics", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 150, 1 April 2018 (2018-04-01), AMSTERDAM, NL, pages 742 - 756, *
TAEKO HAYAKAWA ET AL: "Enhanced anti-tumor effects of the PD-1/PD-L1 blockade by combining a highly absorptive form of NF-kB/STAT3 inhibitor curcumin", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL, , vol. 2, no. Suppl 3, pages P210, *

Also Published As

Publication number Publication date
US12599603B2 (en) 2026-04-14
AU2020343329B2 (en) 2025-07-24
EP4025218A1 (en) 2022-07-13
BR112022003670A2 (pt) 2022-05-24
MX2022002607A (es) 2022-03-25
KR20220054853A (ko) 2022-05-03
US20220354851A1 (en) 2022-11-10
CN114340636A (zh) 2022-04-12
IL290983A (en) 2022-05-01
JP2022546711A (ja) 2022-11-07
JP7631319B2 (ja) 2025-02-18
CA3147071A1 (en) 2021-03-11
WO2021046250A1 (en) 2021-03-11
AU2020343329A1 (en) 2022-03-24
EP4025218A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
JP7564172B2 (ja) 免疫チェックポイント阻害薬と併用するプリナブリンの使用
AU2020343329B2 (en) Methods of treatment
US20250339438A1 (en) Organic compounds
US20250186446A1 (en) Organic compounds
CN108778267A (zh) 包含妥卡雷琐或其类似物的组合物
US20250073230A1 (en) Use of plinabulin in combination with immune checkpoint inhibitors
RU2822394C1 (ru) Способы лечения
HK40066948A (en) Methods of treatment
CN118922191A (zh) 有机化合物
HK40112650A (en) Organic compounds
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina
NZ750444B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 OCT 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 OCT 2025

FGA Letters patent sealed or granted (standard patent)